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ABSTRACT 
Background: There is currently no high grade evidence on which to base decisions about the 
frequency of intravenous cannula re-sites 
Objective: To assess the safety of changing peripheral venous cannulas when clinically 
indicated 
Design: Randomised controlled trial 
Setting: A tertiary referral hospital in Brisbane, Australia 
Participants: 206 hospitalised patients from surgical, medical and orthopaedic wards 
Interventions: Peripheral intravenous cannulas were re-sited only when complications 
occurred (intervention group) or every 3 days (control group). 
Main outcome measures: The primary endpoint was any unplanned cannula removal, the 
secondary outcome was cost.  
Results: Forty six patients had unplanned removals in the intervention group compared with 
41 in the control group [relative risk 1.12, 95% confidence interval 0.81 to 1.55 (p = 0.286)], 
a non-significant difference. Total duration of peripheral cannulation was similar in both 
groups (mean 123.3 hours in the intervention group and 125.9 hours in the control group: P = 
0.82) but significantly more re-sites occurred in the control group (167 in intervention group, 
202 in the control group: p = 0.022). Cost of cannula replacements in the intervention group 
was AUD$3,183.62 and in the control group AUD$3,837.56 (p = 0.006).  
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Conclusion: Re-siting peripheral venous cannulas when clinically indicated compared with 
changing them routinely every 3 days does not lead to more complications and reduces costs.  
 
Keywords: Clinical trials; Cost and cost analysis; Infusions, intravenous  
 
 
 
 
What is already known about this topic: 
 
• Peripheral intravenous cannulation is the most common invasive procedure amongst 
hospitalised patients 
• Each time the integrity of the skin is breached there is an opportunity for invasion by 
pathogenic organisms 
• Current guidelines/recommendations about how often peripheral intravenous 
cannulas should be re-sited has not been tested using an appropriately powered 
randomised controlled trial. 
 
What this paper adds: 
• Unplanned cannula removal rates are not affected by the length of time an individual 
cannula remains in situ 
• Costs are reduced when intravenous peripheral cannulas are re-sited when clinically 
indicated compared with re-siting every three days.  
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Introduction 
Among hospitalised patients, intravenous therapy is the most common invasive procedure. It 
is associated with a phlebitis rate of between 2.3% and 35% (Martinez et al., 1994, Tager et 
al., 1983, White, 2001) and an intravenous catheter related bacteraemia rate of approximately 
0.8% (Maki and Ringer, 1991). Responsibility for placement and re-siting these catheters is 
increasingly the duty of registered nurses, who either are part of specialised teams or who 
work in areas such as critical or intensive care, emergency departments or in other locations 
where nursing has a greater degree of autonomy in practice.  
 
 Current guidelines recommend that peripheral intravenous catheters should be re-sited every 
72-96 hours, in adults, to restrict infection potential (O'Grady et al., 2002), and most hospitals 
follow this recommendation. However, the guideline cites only one study to support the 
recommendation. This was a paper published in 1998 and based on data collected 15 years 
ago (Lai, 1998). More recent studies have challenged the need for such frequent re-sites 
(Homer and Holmes, 1998, Bregenzer et al., 1998, White, 2001, Cornely et al., 2002) and 
suggest that dwell times of intravenous cannulas may be safely extended.  Most of the 
investigations  in adults have been either retrospective or prospective observational studies 
based on convenience samples which may have led to sampling bias. Thus the primary 
objective of the present study was to assess the safety of prolonging the time between 
intravenous cannula re-sites using more rigorous methods. The hypotheses for the study are: 
 
1. That more unplanned IV cannula re-sites will occur in the 3-day change group 
(control group) than in the group who have their cannula changed only when a 
complication occurs (intervention group). 
2. That the cost of IV cannulation will be greater in the control group when compared 
with the intervention group. 
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Method 
 
Study population 
Human Research Ethics Committee gave approval to conduct the trial. Participants were 
eligible for the DRIP trial if they were inpatients at the Royal Brisbane and Royal Women's 
Hospital, were at least 18 years of age and expected to have a peripheral venous catheter 
indwelling for at least 4 days. The trial was controversial as it contravened existing 
guidelines, so we restricted entry to those who had their cannula inserted by a nurse from the 
IV Therapy Team. This enabled us to standardise insertion methods and closely monitor 
insertion sites. We excluded patients with an existing bloodstream infection and those 
receiving immunosupressive treatment. At the time of peripheral catheter insertion, all 
potentially eligible participants were given a trial information leaflet outlining the study. 
Within 72 hours they were asked for their written consent.  
 
Procedure 
The intervention group had their peripheral venous catheter re-sited if clinically indicated. 
The control group had a new peripheral venous catheter re-located to a different site every 3 
days (or when clinically indicated if less than 3 days).  A member of the IV Unit was 
responsible for inserting all initial and replacement catheters. Demographic and other risk 
factors which may have been associated with an IV complication were collected at baseline. 
All medications and infusates were graded on an ‘irritability scale’ (Catney et al., 2001). The 
scale was modified for the study by our hospital pharmacist to include medications received 
by patients during the study, it ranged between 1 (least irritable) and 4 (most irritibale). If the 
patient was receiving more than one additive, we recorded the one with the highest irritability 
score. Vein quality was classified by IV Unit staff on a  6-point scale from ‘extremely 
limited’ to ‘good’ in line with their usual practice. Participants were monitored for the total 
infusion period and followed until 48 hours after catheter removal or until discharge.  
Primary outcome measure 
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We used a composite measure of any unplanned reason for cannula removal. That is, if the 
cannula was removed for any of the following reasons, the patient was considered to have had 
an ‘unplanned’ cannula removal i) leakage around the cannula; ii) infiltration (defined as 
permeation of non-vesicant IV fluid into the interstial compartment, causing swelling of the 
tissue around the site of the catheter); iii) erythema; iv) occlusion/blockage; v) pain; vi) 
accidental removal; vii) local infection at the site of the catheter (defined as erythema with 
cellulitis at the site or pus); viii) phlebitis (defined as the presence of  two or more of the 
following: pain, tenderness, warmth, erythema, swelling, and a palpable cord  (Bregenzer et 
al., 1998, Maki and Ringer, 1991, Monreal et al., 1999) during the course of the infusion and 
up to 48 hours after peripheral venous catheter removal) or  ix) catheter-related blood stream 
infection (based on the isolation of a phenotypically identical organism from a catheter 
segment and a blood culture (Cornely et al., 2002)).  
Secondary outcome Measure 
Cost 
Cost was calculated in two ways, costs associated with cannulas inserted for the 
administration of intermittent IV medication and cost associated with IV cannulas inserted for 
continuous infusion. For the first group, which we estimated to be 25% of the population we 
calculated a total cost of AUD $14.26. This included 20 minutes nursing time (locating 
patient, preparation and insertion),  a cannula, a 3 way tap, a basic dressing pack, a syringe, 
transparent adhesive dressing, skin disinfection and local anaesthetic per insertion. For 
patients receiving a continuous infusion we calculated a total cost of AUD $21.26 per 
insertion. This included all the above costs plus the additional cost of replacing all associated 
lines, solutions and additives which are discarded when a cannula is changed (ie intravenous 
administration set and 1 litre Sodium Chloride 0.09%. 
Sample size 
We based our sample size on an estimated 40% rate of unplanned cannula removals (estimate 
from the IV Unit leader). We calculated that a sample size of  105 in each arm of the study 
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would be needed to detect a 50% reduction in the primary outcome measure  (two tailed, α = 
0.05, power 80%).   
 
Randomisation and blinding 
Randomisation was by a computer generated random number list, stratified by oncology 
status. Allocation to the control or treatment group was made by phoning a person who was 
independent of the recruitment process and blind to baseline clinical data. The person 
assessing the outcome (a nurse from the IV Unit) was not blinded to the study group but was 
unassociated with the the study. 
 
Statistical analysis 
We conducted an intention to treat analysis. We analysed the primary outcome using the 2-
sided Fisher’s Exact test and results are presented as relative risks with 95% confidence 
intervals. A Student’s t-test comparison of intervention versus control was used for the 
secondary outcome. All statistical data were analysed using SPSS (Version 12.0, SPSS, INC, 
Chicago, IL). The CONSORT guidelines were followed from the point of eligibility. 
Statistical results are all 2-tailed.  
PLACE FIGURE 1 (Consort statement) HERE  
 
 
 
Results 
Between April 2004 and November 2004 we assessed 1,240 patients who were potentially 
eligible for the study. Amost half (n = 533) did not meet eligibility criteria and a further 501 
were excluded for other reasons (Fig 1). Table 1 shows the characteristics of the groups at 
baseline. Patients enrolled were mostly elderly and over half had at least 2 co-morbid medical 
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conditions. Characteristics associated with  IV cannulation are shown in Table 2. There were 
no statistically significant differences between groups at baseline. 
PLACE TABLE 1AND TABLE 2 HERE 
Primary outcome 
A total of 368 cannulas were inserted in the 206 participants. Forty six patients (44.6%) in the 
intervention group had an unplanned cannula removal compared with 41 (39.8%) in the 
control group. The result was not statistically sgnificant [relative risk 1.12, 95% confidence 
interval 0.81 to 1.55 (p = 0.286)]. The total duration of peripheral cannulation was similar in 
both groups (mean 123.3 hours, SD 88.9 hours in the intervention group and 125.9 hours, SD 
73.0 hours in the control group: p = 0.82) but significantly more re-sites occurred in the 
control group (intervention group 103, control group 161: p = 0.022). Infiltration was the 
most frequent reason for removal (n = 89) and erythema the least frequent (n = 4).  Phlebitis 
was diagnosed on only 3 occasions, twice in the control group and once in the intervention 
group. Each of the patients diagnosed with phlebitis had a concurrent infection (one wound 
infection and two with cellulitis), they were each on antibiotic therapy and their cannulas had 
been in situ for an average of 48.7 hours (range 25 – 77 hours). There were no reported cases 
of bacteremia or local infection during the study.   
 
Secondary Outcome 
There was a significant difference in cost between the two groups (p = 0.006). The total cost 
of cannula changes for the 103 patients in the control group was AUD$3,837.56 compared 
with the total cost for the 103 patients in the intervention group of AUD$3,183.62. 
 
Discussion 
Primary outcome 
The prospective randomised controlled design of the study has allowed us to compare the 
effects of re-siting intravenous peripheral cannulas when clinically indicated, with the 
standard practice of re-siting them every three days. Outcomes were similar in both groups 
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and this concurs with several other prospective, but not randomised studies. For example, in 
an adequately powered observational study, which included patients from medical wards and 
intensive care units, the investigators were unable to demonstrate any increased risk for 
phlebitis (or any of the other outcomes measured) beyond the second day (Bregenzer et al., 
1998). Similarly, in retrospective study of 784 I/V  starts, the rate of phlebitis on days one and 
two was 11.5% dropping to 3.9% by day four (Homer and Holmes, 1998). The authors 
concluded that “there appeared to be less risk in continuing therapy beyond the third day than 
re-starting the therapy” (pp304). In 2001, Catney and colleagues failed to demonstrate any 
increase in phlebitis rates with the passage of time with failure rates being less at 144 hours 
(1.9%) than at 72 hours (2.5%) (Catney et al., 2001). Also in 2001, a prospective investigation 
of 305 peripheral catheters reported 10 cases of infusion phlebitis amongst patients who had 
their catheter in situ for less than 72 hours, none were reported in patients where the dwell 
time was longer (White, 2001). In the same study, there were 3 cases of post-infusion 
phlebitis, these all occured amongst patients whose peripheral vein infusion catheter had been 
in place for less than 72 hours. Finally, phlebitis rates amongst a high risk population of 
oncology and infectious diseases patients were no different when length of cannulation was 
dichotomised to 3 days or less and more than 3 days (Cornely et al., 2002). 
 
Our results also concur with studies underpinning the guideline for IV cannula replacement in 
children (Catney et al., 2001, Cornely et al., 2002, Shimandle et al., 1999), which states "Do 
not replace peripheral catheters unless clinically indicated” (O'Grady et al., 2002; pp761).  
 
Conversely, we are at odds with a recent randomised study where 42.3% of participants in a 
‘change when clinically indicated group’ developed phlebitis compared with 4.8% in a 2-day 
change group (Barker et al., 2004). However there were a number of methodological flaws 
with that study. It was very small; only 47 participants were included with no indication of 
how the sample size was determined. In addition, the principal investigator, who was not 
blinded to group allocation, was responsible for classifying the outcome, providing a potential 
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for reporting bias. Additionally, the phlebitis rate in the ‘change when clinically indicated 
group’ was much higher than those reported in well conducted clinical studies.  
 
 
 Secondary outcome 
Costings used in our study indicate that changing cannulas only when complications occur 
would reduce peripheral IV related expenditure by at least 17%. We project an annual cost 
benefit of approximately AUD $60,300 if cannulas re-sited by the IV Unit are replaced only 
when clinically indicated. Cost savings would be much higher if this policy were to be 
adopted in other areas of the hospital, where the IV Unit are not currently responsible for 
cannula changes.  Our estimates were very conservative, derived from the cost of a basic 
saline infusion and not including the cost of any other IV additives, IV analgesics or IV 
antibiotics, which may need replacing along with the re-site. In trials where there are no 
differences between intervention and control outcomes, the option with a lower cost should be 
chosen. In this case, the weight of evidence from recent studies along with our own findings 
indicates that the practice of routine 3-day peripheral cannula changes should be re-
considered, at least in settings where an IV service exists. Further research is required to test 
if these benefits are sustained when a cannula is inserted by other hospital staff. 
 
Other outcomes 
None of the participants in the study developed bacteremia and our phlebitis rate for cannulas 
inserted by the IV Unit nurses was extremely low at 1.5%. The revised Intravenous Nurses 
Society Standards of Practice states the incidence of peripheral vein infusion thrombophlebitis 
should be no more than 5% in any population (1998) (Anon, 2000) but most studies report 
higher rates (Chee and Tan, 2002, Martinez et al., 1994, White, 2001). Our low phlebitis rate 
prevents any meaningful correlations with risk factors but it was interesting to note that each 
of those with a documented phlebitis had a co-existing infection which was being treated with 
antibiotics. We could find only one other study reporting an association between phlebitis and 
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an infected site remote from the cannula but, in that study, only 5.9% of potential sources of 
catheter related infections were attributed to a co-existing infection (Diener et al., 1996). 
However there is very good evidence from the infection control literature of the relationship 
between wound infection and remote site infections (Edwards, 1976) and this adds 
plausibility to the finding. Future research in the area should include information about 
existing infections.  
 
Taken together, results from recent studies, including our own, challenge the most recent 
guidelines which recommend replacing peripheral intravenous catheters at least every 72-96 
hours. (O'Grady N et al., 2002). In light of recent evidence, it is perhaps timely for guidelines 
recommending the frequency of changes in adults to be re-visited.  
 
Limitations 
Although a large number of patients were ineligible for the study, approximately half of these 
were because it was not anticipated that their cannula would remain in situ for more than 3 
days, or because the cannula had been in place for more than 48 hours before they were able 
to be enrolled. Neither of these reasons should have affected the results.  Of the other reasons 
for exclusion, having an existing blood stream infection, being immunosuppressed or being 
too ill to consent may impact on results being generalised. However, a large proportion of the 
patients we studied were quite elderly and many had a number of co-morbidities, making 
them a vulnerable but typical tertiary hospital population, so we believe our findings remain 
quite robust. A further study is about to commence in which patients excluded in the current 
study will be involved. Ideally, the person diagnosing any IV related complication should 
have been blinded to the study group.  
 
Conclusion 
Cannulation of peripheral veins is a painful yet necessary component of modern medical care. 
Frequent re-sites are distressing for patients, have a significant cost component and may lead 
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to future venous access difficulties. The present study has shown that the risk of an adverse 
outcome is unaffected when cannulas are re-sited based on clinical parameters and not on 
routine and that cost savings may be considerable if cannulas are re-sited only when clinically 
indicated. 
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Figure 1. Patient flow through the trial 
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Table 1 – Baseline characteristics of study participants  
 
 No-change 
(n=103) 
3-Day 
(n=103) 
 
P‡ 
Sex*  
Male 
             Female  
 
50 (48.5) 
53 (51.5) 
 
49 (47.6) 
54 (52.4) 
 
0.50 
 
Mean age in years† 60.22 [16.2] 63.06 [17.3] 0.22 
Reason for admission* 
 
Gastrointestinal 
Vascular 
Oncology 
Other 
 
49 (47.6) 
23 (22.3) 
12 (11.7) 
19 (18.4) 
 
47 (45.6) 
24 (23.3) 
12 (11.7) 
20 (19.4) 
 
0.99 
Past medical history* 
 
Nil 
1 co-morbid medical condition 
2 co-morbid medical conditions 
> 2 co-morbid medical conditions 
 
11 (10.7) 
27 (26.2) 
36 (35.0) 
29 (28.2) 
 
6 (5.8) 
28 (27.2) 
31 (30.1) 
38 (36.9) 
 
0.38 
Has current infection* 
 
Urinary tract 
Respiratory tract 
Wound/cellulitis 
 
2 (1.9) 
9 (8.7) 
20 (19.4) 
 
7 (6.8) 
9 (8.7) 
23 (22.3) 
 
0.09 
0.60 
0.37 
Type of surgery*    
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             Nil 
Gastrointestinal 
Vascular 
Other 
> 1 operation 
46 (44.7) 
30 (29.1) 
13 (12.6) 
8 (7.8) 
6 (5.8) 
41 (39.8) 
31 (30.1) 
17 (16.5) 
7 (6.8) 
7 (6.8) 
0.91 
 
Most recent Hb – mean ( g/dL ) †  
 
119.98 [19.1] 119.13 [17.0] 0.43 
Past history of phlebitis* 5 (4.9) 3 (2.9) 0.36 
Indwelling urinary catheter* 24 (23.3) 19 (18.4) 0.25 
 
* Results expressed as number and (percent) 
† Results presented as mean and [standard deviation] 
‡ Chi square for proportions or Student’s t test for continuous variables 
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Table 2. Baseline infusion related characteristics of study participants   
 No-change 
(n=103) 
3-Day 
(n=103) 
P‡ 
IV cannula gauge* 
          20 gauge 
          22 gauge 
           Other 
 
61 (59.2) 
40 (38.8) 
  2 (1.9) 
 
59 (57.3) 
43 (41.7) 
  1 (1.0) 
 
0.79 
Vein assessment* 
          Poor 
          Fair/good 
 
39 (37.9) 
64 (62.1) 
 
43 (41.7) 
60 (58.3) 
 
0.34 
Receiving infusate* 82 (79.6) 81 (78.6) 0.50 
Mean irritability rating of infusate† 1.77 [0.9] 1.78 [0.9] 0.66 
Receiving IV antibiotics* 64 (62.1) 56 (54.4) 0.16 
Mean irritability rating of antibiotics† 2.51 [0.7] 2.34 [0.7] 0.62 
Receiving other IV medications* 70 (68.0) 68 (66.0) 0.44 
Mean irritability of IV medications† 1.42 [0.6] 1.41 [0.6] 0.85 
Insertion site of IV cannula* 
          All in hand 
          All in forearm 
          Combination of sites 
          Other 
 
26 (52.0) 
57 (57.0) 
17 (34.7) 
3 (42.9) 
 
24 (48.0) 
43 (43.0) 
32 (65.3) 
4 (57.1) 
 
0.08 
Other vascular device in situ* 21 (20.4) 18 (17.5) 0.36 
 
* Results expressed as number and (percent) 
† Results presented as mean and [standard deviation] 
‡ Chi square for proportions or Student’s t test for continuous variables 
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